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Abstract: Block sequential regularized expectation maximization (BSREM)
is a Bayesian penalized-likelihood reconstruction algorithm for PET, which
reaches full convergence without the detriment of deteriorating the image
quality by noise. Therefore, BSREM might have implications particularly
for the detection of small lesions, which may be beneficial in melanoma pa-
tients. Our case of a 70-year-old man with metastasized malignant melanoma
illustrates the impact of such a novel iterative PET reconstruction algorithm.
Whereas the lymph node metastases are seen with the latest generation or-
dered subset expectation maximization reconstruction, the in-transit metasta-
ses are identified straightforward only with BSREM reconstruction.
Key Words: BSREM, malignant melanoma, in-transit metastasis, FDG,
PET/CT, OSEM, PSF
(Clin Nucl Med 2018;43: 370–371)
REFERENCES
1. Read RL, Haydu L, Saw RP, et al. In-transit melanoma metastases: inci-
dence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;
22:475–481.
2. Singnurkar A, Wang J, Joshua AM, et al. 18F-FDG-PET/CT in the staging
and management of melanoma: a prospective multicenter Ontario PET reg-
istry study. Clin Nucl Med. 2016;41:189–193.
3. Covington MF, Curiel CN, Lattimore L, et al. FDG-PET/CT for monitoring
response of melanoma to the novel oncolytic viral therapy talimogene
laherparepvec. Clin Nucl Med. 2017;42:114–115.
4. Mena E, Taghipour M, Sheikhbahaei S, et al. 18F-FDG-PET/CT in the stag-
ing and management of melanoma: a prospective multicenter Ontario PET
registry study. Clin Nucl Med. 2016;41:e403–409.
5. Drouet C, Morel O, Boulahdour H. Bilateral huge incidentalomas of isolated
adrenal metastases from unknown primary melanoma revealed by 18F-FDG
PET/CT. Clin Nucl Med. 2017;42:e51–e53.
6. Baratto L, Park SY, Hatami N, et al. 18F-FDG silicon photomultiplier PET/
CT: a pilot study comparing semi-quantitative measurements with standard
PET/CT. PLoS One. 2017;12:e0178936.
7. Sah BR, Stolzmann P, Delso G, et al. Clinical evaluation of a block se-
quential regularized expectation maximization reconstruction algorithm in
18F-FDG PET/CT studies. Nucl Med Commun. 2017;38:57–66.
8. Enilorac B, Lasnon C, Nganoa C, et al. Does PET reconstruction method
affect Deauville scoring in lymphoma patients? J Nucl Med. 2017. [Epub
ahead of print].
9. Chilcott AK, Bradley KM, McGowan DR. Effect of a Bayesian penalized
likelihood PET reconstruction compared with ordered subset expectation
maximization on clinical image quality over a wide range of patient weights.
AJR Am J Roentgenol. 2018;210:153–157.
10. Parvizi N, Franklin JM, McGowan DR, et al. Does a novel penalized likeli-
hood reconstruction of 18F-FDG PET-CT improve signal-to-background in
colorectal liver metastases? Eur J Radiol. 2015;84:1873–1878.
11. Sampaio Vieira T, Borges Faria D, Azevedo Silva F, et al. The impact of a
Bayesian penalized likelihood reconstruction algorithm on the evaluation
of indeterminate pulmonary nodules by dual-time point 18F-FDG PET/CT.
Clin Nucl Med. 2017;42:e352–e354.
12. Akamatsu G, Ishikawa K, Mitsumoto K, et al. Improvement in PET/CT im-
age quality with a combination of point-spread function and time-of-flight in
relation to reconstruction parameters. J Nucl Med. 2012;53:1716–1722.
13. van der Vos CS, Koopman D, Rijnsdorp S, et al. Quantification, improve-
ment, and harmonization of small lesion detection with state-of-the-art
PET. Eur J Nucl Med Mol Imaging. 2017;44:4–16.
14. Nuyts J, Fessler JA. A penalized-likelihood image reconstruction method for
emission tomography, compared to postsmoothed maximum-likelihoodwith
matched spatial resolution. IEEE Trans Med Imaging. 2003;22:1042–1052.
15. Teoh EJ, McGowan DR, Macpherson RE, et al. Phantom and clinical evalu-
ation of the Bayesian penalized likelihood reconstruction algorithm Q.Clear
on an LYSO PET/CT system. J Nucl Med. 2015;56:1447–1452.
16. Ahn S, Ross SG, Asma E, et al. Quantitative comparison of OSEM and pe-
nalized likelihood image reconstruction using relative difference penalties
for clinical PET. Phys Med Biol. 2015;60:5733–5751.
17. Reynes-Llompart G, Gamez-Cenzano C, Romero-Zayas I, et al. Performance
characteristics of the whole-body discovery IQ PET/CT system. J Nucl Med.
2017;58:1155–1161.
18. Vallot D, Caselles O, Chaltiel L, et al. A clinical evaluation of the impact of
the Bayesian penalized likelihood reconstruction algorithm on PET FDG
metrics. Nucl Med Commun. 2017;38:979–984.
Received for publication December 22, 2017; revision accepted January 28, 2018.
From the Department of Nuclear Medicine, University Hospital Zurich/University
of Zurich, Zurich, Switzerland.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Arwa Aljared, MD, Department of Nuclear Medicine,
University Hospital Zurich/University of Zurich, Rämistrasse 100, 8091 Zurich,
Switzerland. E-mail: Dr.arwa@gmail.com.
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0363-9762/18/4305–0370
DOI: 10.1097/RLU.0000000000002024
INTERESTING IMAGE
370 www.nuclearmed.com Clinical Nuclear Medicine • Volume 43, Number 5, May 2018
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. 18F-FDG-PET/CT imaging of a 70-year-old manwith acral lentiginousmelanoma, using a novel digital PET/CT system
(Discovery MI PET/CT; GE Healthcare, Waukesha, WI). A dose of 267 MBq of 18F-FDG was administered. Coronal maximum
intensity projection PET image reconstructed using ordered subset expectation maximization (OSEM) algorithm and
point-spread function (PSF) (A) shows low uptake at the primary tumor excision site in the left foot (arrowhead). Several lymph
node metastases (arrows) with high FDG uptake (SUVmax, 19.0) are seen in the inguinal and femoral region. On the identical
dataset reconstructed with block sequential regularized expectation maximization (BSREM) (B), 4 additional FDG-avid foci
(arrows) are easily discovered in the left thigh along the lymphatic stream, compatible with in-transit metastases, which was
eventually proven by histopathology. In retrospect, some of them are also hardly seen on the OSEM + PSF reconstruction (A).
Axial fused 18F-FDG-PET/CT image using OSEM + PSF reconstruction (C) at the level of one in-transit metastasis shows only very
subtle uptake (SUVmax, 1.7) close to background activity in the subcutaneous adipose tissue medial to the sartorius muscle.
The same lesion (arrow) is easily identified as distinct focal uptake (SUVmax, 6.1) on the axial fused 18F-FDG-PET/CT image using
BSREM reconstruction, whereas the activity in a vessel nearby is not promoted (D). The American Joint Committee on Cancer
(AJCC) defines in-transit metastases as any skin or subcutaneous metastases that are located more than 2 cm away from the
primary lesion but are not beyond the regional nodal basin. They are considered intralymphatic extensions of the primary
tumor before reaching the nearest lymph node. The incidence of in-transit metastases is 2% to 10% in melanoma patients, with
75% of these patients eventually developing either nodal metastases, systemic metastases, or both.1 18F-FDG-PET/CT is widely
used in the initial staging and therapy monitoring of malignant melanoma patients, particularly in advanced cases.2–5 Recently
introduced digital PET detector technology yields higher intrinsic system sensitivity compared with the latest generation
analog technology.6 PET reconstruction algorithms are known to have potential impact on staging in oncology patients.7–12 In
our case, BSREM yielded a clinically relevant improvement over OSEM + PSF by detecting tiny malignant lesions. Block
sequential regularized expectation maximization is a Bayesian penalized-likelihood reconstruction algorithm for PET, aiming to
improve clinical image quality and allowing for absolute quantification.6,13–15 Block sequential regularized expectation
maximization allows every single image voxel to reach full convergence.16 The penalty is designed such that edges are preserved
while background image noise is kept low.16 Using an optimumpenalized factor (beta) value of 450 as in our case yields a high
contrast recovery and lower background variability in body FDG-PET images.6,11,15,17,18 The use of BSREMmay have implications
notably for the detection of small lesions, such as in-transit metastases as in our case or lymph node metastases.6,10,11 This is
particularly important for malignant melanoma patients, whose prognosis worsens with the presence of in-transit metastases,
and even more so if they are missed.
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